Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

NEVIRAPINE

NEVIRAPINE

Standard Dose
50MG/5ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview NEVIRAPINE is listed in Drugs@FDA under application 207684 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient NEVIRAPINE Form and strength SUSPENSION;ORAL - 50MG/5ML Sponsor CIPLA Submission history Latest submission status date: 2018-12-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview NEVIRAPINE is listed in Drugs@FDA under application 207684 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient NEVIRAPINE Form and strength SUSPENSION;ORAL - 50MG/5ML Sponsor CIPLA Submission history Latest submission status date: 2018-12-21 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.